Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ACP Immunotherapy Workshop /
Can we afford immunotherapy?

13th Oct 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.10.17
Views: 1466

Dr Peter Hall - University of Edinburgh, Edinburgh, UK

Dr Hall speaks with ecancer at the ACP immunotherapy workshop about the barriers to immunotherapy availability through the NHS.

He describes the balance of incentivising drug development with paying for it out of taxpayer contributions, and differences between NICE and the Scottish Medicines Consortium.

For more on the approval and availability of drugs, watch a summary of cost and suitability measures here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation